Gastric antral vascular ectasia

Summary

Gastric antral vascular ectasia (MONDO:0006767) is a disease and 9 clinical trials. A subtype of capillary disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric antral vascular ectasia
Mondo ID	MONDO:0006767
EFO	EFO:1000945
MeSH	D020252
DOID	DOID:2493
NCIT	C84724
SNOMED CT	43935004
UMLS	C0267211
MedGen	82753
GARD	0007877
MedDRA	10051585
Is cancer (heuristic)	no

Also known as: GAVE

Disease family

This is a subtype of capillary disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › capillary disorder › gastric antral vascular ectasia

Related subtypes (3): capillary leak syndrome, breast angiomatosis, capillary lymphangioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01601639	PHASE3	COMPLETED	Endoscopic Band Ligation Versus Argon Plasma Coagulation for the Treatment of Gastric Antral Vascular Ectasia: a Randomized Clinical Trial
NCT00964496	PHASE2	COMPLETED	Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
NCT06306963	Not specified	RECRUITING	Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias
NCT06772480	Not specified	NOT_YET_RECRUITING	Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial)
NCT07127952	Not specified	ENROLLING_BY_INVITATION	Correlations of the Microvascular Abnormalities on NVC (Nail Fold Video Capillaroscopy) and GAVE (Gastric Antral Vascular Ectasia) as Seen on EGD
NCT07169799	Not specified	RECRUITING	Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)
NCT03525366	Not specified	WITHDRAWN	Prospective Evaluation Of Outcomes For Patients Undergoing Radiofrequency Ablation (RFA) Using HALO Ultra Device For Gastric Antral Vascular Ectasia (GAVE)
NCT04388150	Not specified	COMPLETED	Efficacy of Narrow Band Spectrum Endoscopy for the Diagnosis of Gastric Antral Vascular Ectasia in Patients With Liver Cirrhosis
NCT05690750	Not specified	UNKNOWN	Gastric Antral Vascular Ectasia in Patients With Cirrhosis: Risk-factors and Associations.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CHEMBL426123	0	2